TRAP1 regulates the response of colorectal cancer cells to hypoxia and inhibits ribosome biogenesis under conditions of oxygen deprivation

GIUSEPPINA BRUNO1, VALERIA LI BERGOLIS1, ANNAMARIA PISCAZZI1, FABIANA CRISPO2, VALENTINA CONDELLI2, PIETRO ZOPPOLI2, FRANCESCA MADDALENA2, MICHELE PIETRAFESA2, GUIDO GIORDANO1, DANilo SWANN MATASSA1, FRANCA ESPOSITO3 and MATTEO LANDRISCINA1,2

1Medical Oncology Unit, Department of Medical and Surgical Sciences, University of Foggia, I-71122 Foggia; 2Laboratory of Pre-Clinical and Translational Research, IRCCS, Referral Cancer Center of Basilicata, I-85028 Rionero in Vulture, Potenza; 3Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, I-80131 Naples, Italy

Received February 11, 2022; Accepted April 12, 2022

DOI: 10.3892/ijo.2022.5369

Abstract. Metabolic rewiring fuels rapid cancer cell proliferation by promoting adjustments in energetic resources, and increasing glucose uptake and its conversion into lactate, even in the presence of oxygen. Furthermore, solid tumors often contain hypoxic areas and can rapidly adapt to low oxygen conditions by activating hypoxia inducible factor (HIF)-1α and several downstream pathways, thus sustaining cell survival and metabolic reprogramming. Since TNF receptor-associated protein 1 (TRAP1) is a HSP90 molecular chaperone upregulated in several human malignancies and is involved in cancer cell adaptation to unfavorable environments and metabolic reprogramming, in the present study, its role was investigated in the adaptive response to hypoxia in human colorectal cancer (CRC) cells and organoids. In the present study, glucose uptake, lactate production and the expression of key metabolic genes were evaluated in TRAP1-silenced CRC cell models under conditions of hypoxia/normoxia. Whole genome gene expression profiling was performed in TRAP1-silenced HCT116 cells exposed to hypoxia to establish the role of TRAP1 in adaptive responses to oxygen deprivation. The results revealed that TRAP1 was involved in regulating hypoxia-induced HIF-1α stabilization and glycolytic metabolism and that glucose transporter 1 expression, glucose uptake and lactate production were partially impaired in TRAP1-silenced CRC cells under hypoxic conditions. At the transcriptional level, the gene expression reprogramming of cancer cells driven by HIF-1α was partially inhibited in TRAP1-silenced CRC cells and organoids exposed to hypoxia. Moreover, Gene Set Enrichment Analysis of TRAP1-silenced HCT116 cells exposed to hypoxia demonstrated that TRAP1 was involved in the regulation of ribosome biogenesis and this occurred with the inhibition of the mTOR pathway. Therefore, as demonstrated herein, TRAP1 is a key factor in maintaining HIF-1α-induced genetic/metabolic program under hypoxic conditions and may represent a promising target for novel metabolic therapies.

Introduction

Metabolic rewiring, a cellular mechanism of adaptation to an unfavorable microenvironment, supports the proliferation, survival and long-term maintenance of cancer cells (1). In contrast to non-malignant tissues, tumors are characterized by an increased rate of glycolysis to meet their energy demands even in the presence of oxygen, a phenomenon known as aerobic glycolysis or the Warburg effect (2). Warburg metabolism, consisting of a glucose conversion to lactate even when oxygen is available, has emerged as a hallmark of cancer (3) and metabolic rewiring from glycolysis to oxidative phosphorylation (OXPHOS) and vice versa is responsible for driving cancer progression (4).

Solid tumors often contain a hypoxic area and hypoxia has been shown to lead to a poor prognosis in cancer patients (5), due to its potential to increase malignancy, resistance to treatment and the risk of metastasis (6). The major transcriptional regulator of adaptive responses to hypoxia is the hypoxia inducible factor 1 (HIF-1), a heterodimeric complex composed of HIF-1α and HIF-1β/Aryl hydrocarbon receptor nuclear translocator (7,8). Unlike the β-subunit, which is ubiquitously expressed, the α-subunit is oxygen-sensitive and stabilized under hypoxic conditions. The active form of the HIF-1αβ complex induces the expression of a number of hypoxia-responsive genes by binding to hypoxia response element (HRE) (9), including vascular endothelial growth factor (VEGF) (10).
and several metabolic genes, such as glucose transporter 1 (GLUT1) (11), lactate dehydrogenase A (LDHA) (12,13) and pyruvate dehydrogenase kinase 1 (PDHK1) (14,15). This gene expression reprogramming induced by HIF-1α activates angiogenesis and sustains a metabolic reprogramming toward Warburg metabolism (10,16). In this complex scenario, a crucial role is played by molecular chaperones in connecting different intracellular pathways (17). TRAP1 is a member of the HSP90 molecular chaperone family, overexpressed in ~60% of human colorectal carcinomas (CRCs), and whose upregulation occurs early in CRC progression; thus, it is hypothesized that it plays a role in the transition from low- to high-grade adenomas (18). TRAP1 can regulate cancer cell adaptation to stress environmental conditions (19-21) and modulate tumor energy metabolism, promoting glycolysis and inhibiting OXPHOS in a context- and tumor-dependent manner (22). In a recent study by the authors, it was reported that TRAP1 favors Warburg metabolism through increased glucose uptake and lactate production and downregulates OXPHOS both in CRC cell lines and CRC patient-derived spheroids (23). Furthermore, TRAP1 binds and inhibits succinate dehydrogenase and cytochrome oxidase (respiratory chain complexes II and IV, respectively) (24,25) with the downregulation of OXPHOS and succinate accumulation. Since succinate stabilizes HIF-1α by blocking prolyl hydrolases and, thus preventing its degradation following ubiquitination, HIF-1α stabilization has been proposed as the main mechanism underlying the role of TRAP1 in tumor progression (24). Based on this rationale and since no evidence is at present available on TRAP1 function under oxygen deprivation conditions, at least to the best of our knowledge, the present study was designed to address the hypothesis that TRAP1 may be a key regulator of the CRC cell response to hypoxia.

Materials and methods

Cell cultures, reagents and cell transfection procedures. The HCT116 cell line (CCL-247) was purchased from the American Type Culture Collection (ATCC) and cultured in McCoy's 5A medium (cat. no. 26600023, Gibco; Thermo Fisher Scientific, Inc.), supplemented with 10% fetal bovine serum (cat. no. 10270106, Gibco; Thermo Fisher Scientific, Inc.), 1% glutamine (cat. no. 25030024, Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin and streptomycin (cat. N 15140122, Gibco; Thermo Fisher Scientific, Inc.). The 293T cell line (CRL-3216, ATCC) was cultured in Iscove's modified Dulbecco's medium (IMDM cat. no. 12440053, Thermo Scientific, Inc.) and 1% penicillin and streptomycin, 2 mmol/l EDTA, 1% (v/v) Triton X100, 1 mmol/l phenyl-sucrose, 60 mmol/l KCl, 15 mmol/l NaCl, 5% (v/v) glycerol, 2 mmol/l EDTA, 1% (v/v) Triton X100, 1 mmol/l phenylmethylsulfonylfluoride, 2 mg/ml aprotinin, 2 mg/ml leupeptin and 0.2% (w/v) deoxycholate) as previously described (23). All experiments were performed in triplicate.

Glucose uptake and lactate production assays. Glucose uptake and lactate production were measured as previously described (23). All experiments were performed at least in triplicate.

RNA extraction and reverse transcription-quantitative PCR (RT-qPCR). Total RNA was extracted using the RNeasy Plus Mini kit (cat. no. 74034, Qiagen GmbH), according to the manufacturer's instructions and reverse transcribed into cDNA using reverse transcription reagents (Superscript IV Vilo, cat. no. 11756050, Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's instructions. qPCR analyses were performed in the CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad Laboratories, Inc.) using SsoAdvanced™ Universal SYBR®-Green Supermix (cat. no. 1725271, Bio-Rad Laboratories, Inc.), according to the manufacturer's instructions. The reaction was conducted according to the following amplification protocol: 95°C for 3 min, 39 cycles at 95°C for 10 sec, 60°C for 30 sec and 65-95°C for 5 sec. Primers were purchased from MilliporeSigma or Invitrogen (Thermo Fisher Scientific, Inc.) and are listed in Table SI. Gene expression was analyzed according to the 2^ΔΔCq relative quantification method (26) using CFX Maestro software version 1.0 (Bio-Rad Laboratories, Inc.).

Western blot analysis. Cell pellets were lysed in ice-cold RIPA buffer [20 mmol/l Tris (pH 7.5) containing 300 mmol/l sucrose, 60 mmol/l KC1, 15 mmol/l NaCl, 5% (v/v) glycerol, 2 mmol/l EDTA, 1% (v/v) Triton X100, 1 mmol/l phenylmethylsulfonylfluoride, 2 mg/ml aprotinin, 2 mg/ml leupeptin and 0.2% (w/v) deoxycholate] as previously described (27). The protein concentration was measured using the Bio-Rad protein assay kit (cat. no. 5000006, Bio-Rad Laboratories, Inc.), according to the manufacturer's instructions. Samples were resolved by SDS-PAGE using polyacrylamide 4-20% precast gels (Mini-PROTEAN TGE Stain-Free Gels, cat. no. 4568994, Bio-Rad Laboratories, Inc.) and transferred onto a nitrocellulose membrane (Trans-Blot Turbo Transfer Pack, cat.
A 3rd generation lentiviral system was used, that includes pVS-G (pMD2.G; plasmid #12259, Addgene, Inc.), pMDLG/pRRE (plasmid #12251, Addgene, Inc.) and pREV AmpR (pRSV-Rev; plasmid #12253, Addgene, Inc.) plasmids. The propagation of plasmids was performed in the bacterial strain DH5a into LB medium. DNA was isolated using the PureLink™ HiPure Plasmid Midiprep kit (cat. no. K210004, Invitrogen; Thermo Fisher Scientific, Inc.).

The 293T cells were transfected with the pLKO.1 vector coding for shTRAP1 using the calcium phosphate-DNA co-precipitation technique. The cell supernatant containing viral particles was collected, filtered and directly used for cell transduction, or ultracentrifuged (49,100 x g) for 2 h at 7°C for organoid transduction. Lentiviral titers were determined using the qPCR Lentivirus Titration kit (LV900, Applied Biological Materials, Inc.), following the manufacturer’s instructions. For the experiments, the amount of lentiviral supernatant used was calculated to achieve the multiplicity of infection (MOI) of 50. To ensure efficient transduction, the 293T and HCT116 cells were incubated with lentiviral supernatants at 37°C for 24 h in the presence of polybrene (8 µg/ml, cat. no. TR-1003, MilliporeSigma). Antibiotic selection was initiated at 24 h post-transduction and was carried out for 5 consecutive days.

Tumor-derived p9T organoids were trypsinized using TrypLE (cat. no. 12605010, Gibco; Thermo Fisher Scientific, Inc.), mixed with 100 µl concentrated virus, 8 ng/ml polybrene and 10 µM Rho-associated, coiled-coil containing protein kinase inhibitor (Y-27632; cat. no. Y0503, MilliporeSigma) in 15 ml tubes and centrifuged at 600 x g for 1 h at 32°C. Subsequently, the organoids were incubated at 37°C and 5% CO₂ for 6 h. Following incubation, the organoids were washed with Advance DMEM/F12 medium and spun down for 5 min at 160 x g for 4°C to eliminate the virus. Following the removal of the virus-containing medium, organoids were plated in ~50 µl BME (cat. no. 353300502, Bio-Techne Corporation).

Transduced organoids were grown in Advance DMEM/12 full of growth factors and fresh Y-27632 for 3 days after which selection was applied by the addition of puromycin (2 µg/ml, cat. no. A113802, Thermo Fisher Scientific, Inc.) for 4 days.

Gene expression profiles. Total RNA (300 ng) was transcribed for the synthesis of cDNA and biotinylated cRNA, according to the protocol of the Illumina TotalPrep RNA (cat. no. AMI1791, Ambion; Thermo Fisher Scientific, Inc.) amplification kit. The hybridization, marking and scanning of 750 ng cRNA was performed on the Illumina Human HT12 v4.0 Expression BeadChip array (Illumina Inc.), following the standard protocol. All analyses were performed in triplicate for each sample. The BeadChip was then dried and scanned using the Illumina HiScanHQ system (Illumina Inc.). Data analysis was carried out through the free/open source environment R/Bioconductor (28). Probes with a low quality of fluorescence intensity signal were excluded from the subsequent analysis steps. Normalization was performed using the nqc procedure, with a background correction through internal controls followed by Quantile Normalization. The differential analysis between the experimental conditions and the normalization were performed using the limma package (29).

shTRAP1 p9T organoids. Human p9T CRC organoids were generated by the Jacco van Rheenen Research Group at the Department of Molecular Pathology of Netherlands Cancer Institute of Amsterdam (NKI-AVL) and kindly provided to the authors’ laboratory. Organoids were cultured in a humidified atmosphere at 37°C and 5% CO₂ with basal culture medium [Advanced DMEM/F12 (cat. no. 12634028, Gibco; Thermo Fisher Scientific, Inc.), 10 mM HEPES (cat. no. 15630056, Gibco; Thermo Fisher Scientific, Inc.), 2 mM Glutamax (cat. no. 35050061, Gibco; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and streptomycin (cat. no. 15140122, Gibco; Thermo Fisher Scientific, Inc.)] supplemented with 10% R-Spondin conditioned medium, 10% Noggin conditioned medium, 1X B27 (cat. no. 17504001, Gibco; Thermo Fisher Scientific, Inc.), 1.25 mM n-acetyl cysteine (cat. no. A9165, MilliporeSigma), 10 mM nicotinamide (cat. no. N0636, MilliporeSigma), 500 mM A83-01 (cat. no. SML0788, MilliporeSigma), 3 µM SB202190 (cat. no. CAY-10010399, Vinci-Biochem), 50 ng/ml human recombinant EGF (cat. no. 354052, BD Biosciences), 10 nM Leu15-Gastrin (cat. no. G9145, MilliporeSigma) and 10 nM prostaglandin E2 (cat. no. 14010, Vinci-Biochem). To confirm correct sample identity, the organoids were regularly tested by corrected sample identity, the organoids were regularly tested by

Gene expression profiles. Total RNA (300 ng) was transcribed for the synthesis of cDNA and biotinylated cRNA, according to the protocol of the Illumina TotalPrep RNA (cat. no. AMI1791, Ambion; Thermo Fisher Scientific, Inc.) amplification kit. The hybridization, marking and scanning of 750 ng cRNA was performed on the Illumina Human HT12 v4.0 Expression BeadChip array (Illumina Inc.), following the standard protocol. All analyses were performed in triplicate for each sample. The BeadChip was then dried and scanned using the Illumina HiScanHQ system (Illumina Inc.). Data analysis was carried out through the free/open source environment R/Bioconductor (28). Probes with a low quality of fluorescence intensity signal were excluded from the subsequent analysis steps. Normalization was performed using the nqc procedure, with a background correction through internal controls followed by Quantile Normalization. The differential analysis between the experimental conditions and the normalization were performed using the limma package (29).

shTRAP1 p9T organoids. Human p9T CRC organoids were generated by the Jacco van Rheenen Research Group at the Department of Molecular Pathology of Netherlands Cancer Institute of Amsterdam (NKI-AVL) and kindly provided to the authors’ laboratory. Organoids were cultured in a humidified atmosphere at 37°C and 5% CO₂ with basal culture medium

Gene expression profiles. Total RNA (300 ng) was transcribed for the synthesis of cDNA and biotinylated cRNA, according to the protocol of the Illumina TotalPrep RNA (cat. no. AMI1791, Ambion; Thermo Fisher Scientific, Inc.) amplification kit. The hybridization, marking and scanning of 750 ng cRNA was performed on the Illumina Human HT12 v4.0 Expression BeadChip array (Illumina Inc.), following the standard protocol. All analyses were performed in triplicate for each sample. The BeadChip was then dried and scanned using the Illumina HiScanHQ system (Illumina Inc.). Data analysis was carried out through the free/open source environment R/Bioconductor (28). Probes with a low quality of fluorescence intensity signal were excluded from the subsequent analysis steps. Normalization was performed using the nqc procedure, with a background correction through internal controls followed by Quantile Normalization. The differential analysis between the experimental conditions and the normalization were performed using the limma package (29).
Functional enrichment analysis was carried out through the Gene Set Enrichment Analysis (GSEA) (30) computational method and the MsigDB database (31) for the collection of annotated gene sets, focusing on the following categories: Hallmark, Gene Ontology and Pathways. The gene expression data generated in the present study have been deposited in the ArrayExpress database at EMBL-EBI (www.ebi.ac.uk/array-express) under the accession no. E-MTAB-10563.

Analysis of public datasets. TRAP1 expression analysis in CRC samples, compared with normal tissue, was performed using the TNMplot database (https://www.tnmplot.com/). The platform directly compares tumor and normal samples and performs a Mann-Whitney U or Kruskal-Wallis tests or a paired Wilcoxon test (in case of availability of paired normal and adjacent tumor) for statistical significance (32).

Statistical analysis. The unpaired t-test was performed using the t-test Calculator of GraphPad (online version) for the analysis of metabolic tests in silenced cells and related controls (Fig. 1C and D). Data are reported as mean values of least three independent experiments (± SD). RT-qPCR data were analyzed using two-way ANOVA and Sidak's multiple comparisons test. Statistical analysis was performed using GraphPad 7.0 software (GraphPad Software, Inc.). A value of P<0.05 was considered to indicate a statistically significant difference.

Results

TRAP1 promotes hypoxia-induced metabolic rewiring in CRC cells via HIF-1α stabilization. In the preliminary analyses, TNMplot gene chip data were used to confirm the increased expression of TRAP1 in human CRC samples (n=160) compared to normal human colorectal mucosa (n=160). Notably, while the normal colorectal mucosa was characterized by a low TRAP1 mRNA expression, a significant upregulation of TRAP1 expression was observed in malignant tissues (Fig. S1A) (P<0.001 Kruskal-Wallis test). Considering that hypoxia is the main stimulus to boost glycolytic
metabolism in cancer cells (12,33-36), in order to establish the role of TRAP1 in hypoxia-induced metabolic rewiring, human CRC cells were used in the present study and in preliminary experiments; the optimal time for HCT116 cell exposure to 0.5% hypoxia to induce HIF-1α stabilization was evaluated. Western blot analysis revealed that HIF-1α maximal stabilization was observed after 4 h of exposure of the cells to 0.5% O2 compared to normoxic conditions (20% O2; Fig. 1A). In these experiments, HCT116 cells exposed to 250 µM deferoxamine for 6 h were used as a positive control.

To examine the role of TRAP1 in controlling HIF-1α stabilization in CRC, HCT116 cells were transiently silenced for TRAP1 and exposed to 4 h of hypoxia or normoxia and evaluated for HIF-1α stabilization using western blot analysis. Of note, although there were no significant differences in HIF-1α gene expression under the current experimental conditions (Fig. 1B, left panel), TRAP1 silencing induced a partial inhibition of HIF-1α stabilization at the post-translational level under hypoxic conditions (Fig. 1B, right panel).

In subsequent experiments, the association between TRAP1-mediated HIF-1α stabilization and its role in metabolic adaptive responses to reduced oxygen availability was investigated. Thus, TRAP1-silenced HCT116 cells were exposed to 0.5 and 20% O2 for 4 h and analyzed for glucose uptake and lactate production. As was expected, hypoxia markedly enhanced both 2-DG uptake (Fig. 1C) and lactate production (Fig. 1D) in a high-TRAP1 background (siNEG). Of note, TRAP1 silencing significantly decreased 2-DG uptake (Fig. 1C) and partially impaired lactate production (Fig. 1D) under hypoxic conditions, thus suggesting that TRAP1 is required for hypoxia-induced metabolic rewiring.

TRAP1 sustains HIF-1α-induced transcriptional reprogramming in CRC cells and patient-derived organoids. To functionally characterize TRAP1-dependent HIF-1α stabilization in CRC, the role of TRAP1 in the HIF-1α-mediated transcriptional reprogramming of metabolic genes under hypoxic conditions was evaluated. HCT116 cells transiently silenced for TRAP1 were incubated for 8 and 24 h at 20 and 0.5% O2 and assayed for the expression of both TRAP1 (Fig. S1B) and HIF-1α-inducible genes commonly involved in metabolic and angiogenic pathways (i.e., GLUT1, GLUT3, VEGFA, LDHA, PDK1, PKM2) (Fig. 2). Of note, TRAP1-silenced HCT116 cells failed to significantly activate the expression of some of the evaluated genes after 8 h of hypoxia compared to the control cells; the differential expression of GLUT3 (P<0.01)
and PDK1 (P<0.001) was statistically significant (Fig. 2A). Consistently, TRAP1 silencing resulted in the reduced expression of all tested genes under 24 h of hypoxia (P<0.001; Fig. 2B). Under normoxic conditions, no significant differences were observed between the TRAP1-silenced and control cells at all time points, with similar expression levels observed for all tested genes (Fig. 2A and B). In parallel experiments, western blot analysis was used to evaluate HIF-1α stabilization and the expression of certain HIF-1α-target genes, i.e., GLUT1, LDHA and MCT4 in a high vs. low TRAP1 background under hypoxic conditions (Fig. 2C). Consistent with the RT-qPCR data, TRAP1 silencing led to the lower stabilization of HIF-1α and to lower levels of GLUT1, LDHA and MCT4 under hypoxic conditions compared to the control cells.

These experiments were further extended to a 3D-model of human CRC organoids, based on the rationale that the growth of organoids within a 3D matrix favors the spontaneous generation of hypoxic areas, as observed in tumors (37). For these experiments, pMOCK and TRAP1-silenced p9T organoids were generated. Four different shTRAP1 lentiviruses (#1, #2, #3 and #4) were first tested for the efficiency of transfection in both 293T and HCT116 cells evaluating TRAP1 silencing using RT-qPCR and western blot analysis (Fig. S1C, left and right panels, respectively), and shTRAP1 #1 and shTRAP1 #3 lentiviruses were selected for their highest silencing effectiveness. In subsequent experiments, shTRAP1 #1 and shTRAP1 #3 were tested for the efficiency of transduction in p9T organoids (Fig. S1D) and shTRAP1 #1 p9T organoids were used for further experiments aimed at validating the role of TRAP1 in the regulation of HIF-1α transcriptional activity. pMOCK and TRAP1-silenced p9T organoids were incubated for 8 and 24 h at 0.5 and 20% O2 and analyzed using RT-qPCR for TRAP1 (Fig. S1E) and HIF-1α inducible genes (Fig. 3) expression levels. The majority of genes exhibited a significant and progressive upregulation in a TRAP1 high expression background under hypoxic conditions starting from 8 h (Fig. 3A) and reaching the highest level at 24 h (Fig. 3B). Notably, TRAP1 silencing resulted in a decreased expression of all tested genes under hypoxic conditions (Fig. 3), with maximal statistical significance at 24 h, as observed in the HCT116 cells.

**TRAP1 silencing promotes ribosomal biogenesis under hypoxic conditions.** As data described above demonstrating a role of TRAP1 in hypoxia-induced gene expression reprogramming, a whole genome expression profiling was performed in TRAP1-silenced and control HCT116 cells exposed to normoxia and hypoxia for 24 h. As was expected, oxygen deprivation promoted significant gene expression reprogramming with 2,665 downregulated and 2,041 upregulated genes compared to the normoxic control (abs logFC ≥0.60, P<0.05). Furthermore, 1,071 genes were differentially expressed (347 downregulated and 724 upregulated) in TRAP1-silenced compared to control HCT116 cells under hypoxic conditions (abs logFC ≥0.60, P<0.05) (Table SII).

GSEA was performed to obtain functional enrichments of differentially expressed genes focusing on the following categories: Hallmark, Gene Ontology (GO) and Pathway (abs enrichment score ≥0.60, P<0.05) (Table SIII). Although very few Hallmarks were enriched, the two most upregulated Hallmarks under hypoxic conditions were HYPOXIA and ANGIogenesis, confirming that, under the current experimental conditions, hypoxic stress regulated gene expression to promote oncogenic and angiogenetic pathways (10-16). Furthermore, several GOs and Pathways were functionally regulated in our experimental conditions. In particular, 453 (227 downregulated and 226 upregulated) and 201 (62 downregulated and 139 upregulated) GOs were enriched comparing hypoxia (siNEG 0.5% O2) vs. normoxia (20% O2) for (A) 8 h and (B) 24 h. P-values indicate statistically significant differences (P<0.01 and ***P<0.001 by comparing pMOCK 0.5% O2 vs. pMOCK 20% O2 and shTRAP1#1 0.5% O2 vs. pMOCK 0.5% O2). TRAP1, TNF receptor-associated protein 1; HIF-1α, hypoxia inducible factor 1α.
Instead, none of these GOs was enriched following TRAP1 silencing under normoxic conditions (siTRAP1 20% O₂ vs. siNEG 20% O₂).

To validate the possible role of TRAP1 in sustaining the ribosome biogenesis inhibition under hypoxic conditions, six genes were selected (i.e., IMP3, LTV1, PWP2, RCL1, RRS1 and UTP3) commonly involved in different steps of ribosome biogenesis and maturation and differentially expressed in the current experimental conditions, thus contributing to the enrichment of previous GO categories (abs logFC ≥0.60, P<0.05). The expression levels of these genes were evaluated using RT-qPCR in both HCT116 cells and p9T organoids silenced or not for TRAP1 and exposed to hypoxia for 24 and 8 h, respectively (Fig. 4B and C). These time points were selected based on data reported in Figs. 2 and 3, demonstrating an earlier transcriptional reprogramming in response to hypoxia in CRC organoids. No difference in expression was observed for all tested genes in TRAP1-silenced cells (Fig. 4B) and shTRAP1#1 p9T organoids (Fig. 4C) compared to controls under normoxic conditions; this was consistent with the GSEA data demonstrating no enrichment of ribosome biogenesis/assembly GO categories under normoxic conditions. Conversely, as was expected, the hypoxic stimulus significantly suppressed the expression of these genes in both the CRC experimental models and TRAP1 silencing attenuated the inhibitory effects of hypoxia by promoting a higher expression of these genes under hypoxic conditions (Fig. 4B and C). Two genes (i.e., PWP2 and RCL1) were undetectable in p9T organoids and, thus, are not illustrated in Fig. 4.

mTOR pathway is likely involved in the TRAP1 regulation of ribosome biogenesis. Based on the hypothesis that the TRAP1 modulation of ribosome biogenesis under hypoxic conditions may involve the mTORC1/p70S6K pathway, western blot analysis was performed to evaluate the phosphorylation status of p70S6K, a master regulator of protein synthesis and ribosome biogenesis, in TRAP1-silenced HCT116 cells exposed to hypoxia and treated with the mTOR inhibitor everolimus at 1 µM for 24 h (Fig. 5A). Unlike oxygen deprivation that suppressed p70S6K phosphorylation, TRAP1 silencing enhanced p70S6K activation/phosphorylation compared to the respective controls and this occurred both under normoxic and hypoxic conditions. Moreover, the mTOR inhibitor, everolimus,
hampered p70S6K phosphorylation under normoxic and hypoxic conditions, and in high and low TRAP1 expression backgrounds (Fig. 5A).

To corroborate the link between the TRAP1 regulation of the mTOR pathway and its control of ribosome biogenesis under hypoxic conditions, four ribosome biogenesis-related genes (i.e., IMP3, LTV1, RRS1, and UTP3) were further evaluated using RT-qPCR in TRAP1-silenced cells exposed to normoxia and hypoxia for 24 h in the presence or absence of 1 µM everolimus. Data are reported as the fold change (FC) increase in gene expression in TRAP1-silenced cells compared to the respective control under normoxic or hypoxic conditions and in the presence or absence of everolimus. As observed in Fig. 4A, TRAP1 silencing resulted in the upregulation of these genes under hypoxic conditions, and this occurred in parallel with mTOR signaling activation (Fig. 5A). Of note, mTOR signaling inhibition by everolimus in TRAP1-silenced cells attenuated the upregulation of these genes (Fig. 5B). According to previously described data, no significant differences (FC <1.5) were observed after TRAP1 silencing under normoxic conditions (siTRAP1 20% O2 vs. siNEG 20% O2).

Figure 5. TRAP1 regulation of ribosome biosynthesis occurs through mTOR signaling regulation. (A) HIF-1α, P70S6K and p-P70S6K western blot analysis in TRAP1-silenced HCT116 cells exposed to hypoxia (0.5% O2) or normoxia (20% O2) for 24 h in the presence or absence of 1 µM everolimus. Densitometric analysis results are reported (nd, not detected). (B) Reverse transcription-quantitative PCR analysis of ribosome biogenesis-related genes in TRAP1-silenced HCT116 cells exposed to hypoxia (0.5% O2) or normoxia (20% O2) for 24 h in the presence or absence of 1 µM everolimus. Data are expressed as the FC increase of gene expression in TRAP1-silenced cells compared to the respective control under normoxic or hypoxic conditions, and in the presence or absence of everolimus. Statistically significant differences among FC values are indicated as *P<0.05, **P<0.01 and ***P<0.001. FC, fold change; TRAP1, TNF receptor-associated protein 1; HIF-1α, hypoxia inducible factor 1α.
Discussion

CRC is responsible for 10% of all cancer types, affecting almost 1.9 million new individuals each year (38) and its mortality rate results in almost 880,000 deaths/year, rendering CRC the second-leading cause of cancer-related deaths (39,40). Despite important advancements in CRC therapy, the vast majority of patients with metastatic disease experience disease progression in response to current treatments and thus, the identification of novel reliable biomarkers and/or targetable pathways associated with CRC onset and progression is required. In this context, metabolic pathways are currently regarded as novel therapeutic targets in solid tumors (41,42), based on the rationale that metabolic reprogramming is considered a hallmark of cancer and supports cancer cell growth and proliferation as well as cell adaptation to unfavorable microenvironments (43).

A frequent stressful condition for solid tumors is the limited availability of oxygen, to which cancer cells can rapidly adapt by activating several survival pathways and, among others, stabilizing the transcription factor HIF-1α, which plays a fundamental role in mediating cellular adaptive responses, inducing the expression of several metabolic genes (11-15) and inhibiting high energy consuming processes (44-47). Indeed, HIF-1α is widely considered the master regulator of cancer cell response to oxygen deprivation and its activation favors a rapid and sustained reprogramming of cancer cells, leading to the induction of angiogenesis and metabolic rewiring towards Warburg metabolism (10,16).

Molecular chaperones function as hub proteins connecting metabolic pathways and cancer cell reprogramming mechanisms (22,48). The authors have previously reported that TRAP1 is upregulated in human CRCs (18,49) and that its expression is directly associated with a poor clinical outcome (18), drug resistance (49) and the inhibition of mitochondrial respiration (24). Recently, it emerged that high TRAP1 levels enhance Warburg metabolism in CRC tissues, patient-derived spheroids and cell lines and that this molecular chaperone can modulate glycolysis controlling PFK1 activity/stability (23). Furthermore, it has already been reported that TRAP1 is involved in HIF-1α stabilization under normoxic conditions and that this process occurs downstream of TRAP1 inhibition of succinate dehydrogenase and respiratory chain (24). Indeed, TRAP1 inhibits complexes II and IV of the respiratory chain with consequent succinate accumulation and favors HIF-1α stabilization due to inhibition of prolyl hydroxylases and HIF-1α degradation (24,25).

In the present study, the role of TRAP1 in controlling cell response to hypoxia was investigated in CRC cell models, using both stabilized cell lines and organoids. It was observed that TRAP1 supports hypoxia-induced metabolic rewiring, increases glucose intake and lactate production and supports HIF-1α stabilization under hypoxia, thus favoring cellular adaptation to oxygen deprivation. Furthermore, TRAP1-mediated HIF-1α stabilization functionally sustains HIF-1α-dependent gene expression reprogramming in both human CRC cells and patient-derived organoids. Thus, it can be hypothesized that TRAP1 is responsible for HIF-1α stabilization under either hypoxic or normoxic conditions, and that this is likely finalized to reprogram tumor metabolism and sustain the oncogenic program induced by hypoxia.

In a translational perspective, it is important to underline that these observations were not only reproduced, but also more evident in CRC organoids, a tridimensional tumor model that resembles several characteristics of human solid tumors (50-52). In particular, the data of the present study demonstrated an earlier transcriptional reprogramming in response to hypoxia in organoids compared to monolayer cells, since their growth within a 3D matrix already promotes the formation of spontaneous hypoxic area which characterize solid tumors (37). 2D cell cultures cannot reproduce the spatial oxygen gradient and spatial heterogeneity observed in vivo in tumors (53), as cancer cells are exposed to a fixed concentration of oxygen partial pressure. Therefore, it is not surprising that the 3D organoid model has often recently been used to mimic hypoxic conditions and in vivo intratumoral heterogeneity (54). Furthermore, the present study suggested that a low TRAP1 expression background induced a greater inhibitory effect on HIF-1α target gene expression under hypoxic conditions in p9T organoids compared to HCT116 cells, and this can be explained by the different cell system and the higher efficacy and stability of shRNA silencing by lentiviral transduction technology.

The adaptive response to hypoxic stress also involves the inhibition of high-energy consuming processes as ribosome biogenesis and protein synthesis (44-47). Indeed, hypoxia induces the inhibition of the mTORC1 kinase (47,55-57), a master regulator of cellular growth and proliferation and mRNA translation (58,59), mTORC1 is a conserved serine/threonine kinase that phosphorylates downstream substrates involved in protein synthesis as eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) and ribosomal protein kinase S6 (S6K1 or p70S6K) (60). The activation of mTORC1 stimulates protein synthesis and cell growth by targeting effectors of both translation efficiency by existing ribosomes and synthesis of new ribosomes (61). In particular, mTORC1 coordinates the synthesis of ribosomal RNA (rRNA) and ribosomal proteins, the major constituents of the ribosome (62-66). Indeed, mTORC1/p70S6K signaling is required for the translation of mRNAs with 5’-terminal oligopyrimidine tract (5’-TOP) sequences, among which many encode for ribosomal proteins or regulators of translation (67-70).

Additionally, p70S6K indirectly enhances the transcription of the 45S ribosomal gene (rDNA) that encodes for 18S, 28S and 5.8S rRNAs (63). In the present study, gene expression analysis performed under hypoxic conditions and in a low vs. high TRAP1 expression background, suggests that ribosome biosynthesis is a main process downregulated in response to oxygen deprivation and this requires high TRAP1 expression. This observation is consistent with the findings of other studies suggesting that TRAP1 influences adaptive biosynthetic processes responsible for the optimization of cancer cell response to stress (71), with TRAP1 being responsible for the cell response to endoplasmic reticulum stress (72), the quality control of mitochondria-destined proteins (73) and the attenuation of protein synthesis (70). Furthermore, previous research by the authors has demonstrated a role of TRAP1 in regulating p70S6K phosphorylation and the cap-mediated translation pathway in cancer cells (74). Thus, it can be hypothesized that TRAP1 is at the crossroads between the HIF-1α and mTORC1 pathways, both involved in cell responses to environmental
stress conditions. HIF-1α is responsible for mTORC1 inhibition (47,55-57) and as mTORC1 signaling is a key regulator of ribosome biogenesis and protein synthesis (60-70), taken together, these data suggest that this network is finalized at optimizing metabolic and biosynthetic processes in cancer cells under conditions of oxygen deprivation, thus, favoring the adaptation to a condition of substrates and energy restriction. Of note, the upregulation of such a network in cancer cells may provide survival and adaptive mechanisms that sustain cancer progression in a hostile environment. However, it is important to underline that these data do not fully demonstrate the mechanistic link between HIF-1α stabilization, mTORC1 inhibition and ribosome biogenesis downregulation in a high TRAP1 expression background; thus, further studies are required to depict the mechanisms involved at the molecular level.

The findings of the present study support the hypothesis that the intricate process of ribosomal subunits synthesis and maturation is controlled by the TRAP1/HIF-1α/mTORC1 network at multiple steps. In this context, TRAP1 pathways indirectly control the expression of several genes (i.e., PWP2, IMP3, UTP3, RCL1, LTV1 and RRS1) coding for proteins playing a role in different steps of ribosome production (75-85). Their expression is downregulated in parallel with mTORC1 inhibition under hypoxic conditions in a high TRAP1 expression background, it is preserved upon TRAP1 silencing under oxygen deprivation conditions, and it is downregulated upon mTOR inhibition in a low TRAP1 expression background. Taken together, these data suggest that the TRAP1 regulation of ribosome biosynthesis under hypoxic conditions occurs through mTORC1 signaling regulation and that this involves the modulation of multiple enzymes.

In conclusion, the results of the present study support a role of TRAP1 in favoring human CRC adaptive responses to oxygen deprivation. Indeed, TRAP1 i) controls HIF-1α stabilization and maximizes Warburg metabolism in response to hypoxia; ii) is able to sustain the oncogenic program induced by hypoxia; and iii) modulates ribosome biogenesis in response to hypoxia to limit cellular energy consumption and this occurs through the mTOR pathway inhibition. Thus, TRAP1 may be considered a potential target for developing innovative therapies aimed at blocking molecular mechanisms that allow cancer cells to survive to unfavorable environmental conditions.

Acknowledgements

The authors would like to thank the research group of Professor Jacco van Rheenen for their cooperation with the generation of organoids, using samples from NKI-AVL Biobank.

Funding

The present study was supported by the ‘5 per mille’ 2018-2019 LILT Investigator Grant. The present study was also supported by PON AIM R&I 2014-2020-1879351-2. This manuscript has been published with the financial support of the Department of Medical and Surgical Sciences of the University of Foggia (project code FINATENO_DIRETTO_ASSNEQUALITA_MEDCHIR_2021) and the University of Foggia (Fondo per i Progetti di Ricerca di Ateneo-PRA 2020).

Available of data and materials

All data generated or analyzed during this study are included in this published article (and in the supplementary files).

Author’s contributions

ML conceived the study and designed the experiments. VLB performed the metabolic experiments and generated the TRAP1-silenced organoids in collaboration with the research group of Professor Jacco van Rheenen (mentioned above). GB and VLB performed the RT-qPCR analysis. VLB and AP performed the western blot analysis. FC, VC and MP performed the whole genome gene expression profiling. PZ, GB and AP analyzed the whole genome gene expression profiling data. FM contributed to the metabolic experiments. GG, DSM and FE assisted in the design of the experiments and in the analysis of the data. GB and ML wrote the manuscript with the assistance of GG, DSM and FE. All authors have read and approved the final manuscript. GB, VLB, VC and PZ confirm the authenticity of all the raw data.

Ethics approval and consent to participate

Organoids were generated by the Nederlands Kanker Instituut-Antoni van Leeuwenhoek (NKI-AVL) and provided to the authors’ laboratory according to an MTA for Academic Institutions. Organoids were generated in accordance with all applicable Nederland laws and regulations, including but not limited to patient’s informed consent and in accordance with the NKI-AVL Institutional Review Board procedure, and the approval of the Medical Ethical Committee (MEC) of the NKI-AVL. Thus, according to the MTA, the organoids were used only for research scopes following the NKI-AVL institutional indications.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Vander Heiden MG and DeBerardinis RJ: Understanding the intersections between metabolism and cancer biology. Cell 168: 657-669, 2017.
2. Liberti MV and Locasale JW: The Warburg effect: How does it benefit cancer cells? Trends Biochem Sci 41: 211-218, 2016.
3. Schwartz L, Supuran CT and Alfarouk KO: The Warburg effect and the hallmarks of cancer. Anticancer Agents Med Chem 17: 164-170, 2017.
4. Yu L, Lu M, Jia D, Ma J, Ben-Jacob E, Levine H, Kaipparettu BA and Onuchic JN: Modeling the genetic regulation of cancer metabolism: Interplay between glycolysis and oxidative phosphorylation. Cancer Res 77: 1564-1574, 2017.
5. Jing X, Yang F, Shao C, Wei K, Xie M, Shen H and Shu Y: Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer 18: 157, 2019.
6. Zhang Y, Zhang H, Wang M, Schmid T, Xin Z, Kozhuharova L, Yu WK, Huang Y, Cai F and Biskup E: Hypoxia in breast cancer: scientific translation to therapeutic and diagnostic clinical applications. Front Oncol 11: 652266, 2021.
7. Miranda E, Nordgren IK, Male AL, Lawrence CE, Hoakwe F, Cuda F, Court F, Fox KR, Townsend PA, Packham GK, et al.: A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. J Am Chem Soc 135: 10418-10425, 2013.

8. Burslem GM, Kyle HF, Nelson A, Edwards TA and Wilson AJ: Hypoxia inducible factor (HIF) as a model for studying inhibition of protein-protein interactions. Chem Sci 8: 4188-4202, 2017.

9. Nagao A, Kobayashi M, Koyasu S, Chow CCT and Harada H: HIF-1-dependent reprogramming of glycolytic metabolic pathway of cancer cells and its therapeutic significance. Int J Mol Sci 20: 238, 2019.

10. Saponaro C, Malfettone A, Ranieri G, Danza K, Simone G, Paradiso A and Mangia A: VEGF, HIF-1α expression and MVD as an angiogenic network in familial breast cancer. PLoS One 8: e53070, 2013.

11. Shen LF, Zhou SH and Yu Q: Relationships between expression of glucose transporter protein-1 and hypoxia inducible factor-1α, prognosis and 5-FDGA uptake in laryngeal and hypopharyngeal carcinomas. Transl Cancer Res 9: 2824-2837, 2020.

12. Sementi GL: HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest 123: 3664-3671, 2013.

13. He G, Yi J, Bo Z and Wu G: The effect of HIF-1α on glucose metabolism, growth and apoptosis of pancreatic cancerous cells. Oncol Lett 13: 174-180, 2017.

14. Goodwin J, Choi H, Hsieh MH, Neugent ML, Ahn JM, Hayenga HN, Singh PK, Shackelford DB, Lee IK, Shulaev V, et al.: Targeting hypoxia-inducible factor-1α/p53 pyruvate dehydrogenase kinase 1 axis by dichloroacetate suppresses blemmycin-induced pulmonar y tumors in mice. J Am J Respir Cell Mol Biol 58: 216-231, 2018.

15. Kiersan SJ and Taylor CT: Regulation of glycolysis by the hypoxia-inducible factor (HIF): Implications for cellular physiology. J Physiol 599: 23-37, 2021.

16. Samec M, Liskova A, Koklesova L, Mersakova S, Strnadel J, Kierans SJ and Taylor CT: Regulation of glycolysis by the hypoxia-inducible factor-1α expression in human colorectal carcinomas. Oncotarget 8: 21229-21240, 2017.

17. Liberton A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, et al.: Definition of a ‘next-generation’ biomarker (review). Int J Oncol 45: 11179-11202, 2020.

18. Shah AN, Alam MM, Cao T and Zhang L: The role of ribosomes in mediating hypoxia response and tolerance in Eukaryotes. Biomed Pharmacother 141: 102983, 2021.

19. Galluzzi L, Kepp O, Vander Heiden MG and Kroemer G: Molecular chaperone TRAP1 regulates a metabolic switch (C(T)) method. Methods 25: 402-408, 2001.
50. Van de Wetering M, Francies HE, Francis JM, Bounova G, Iorio F, Pronk A, van Houdt W, van Gorp J, Taylor-Weiner A, Kester L, et al.: Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161: 935-945, 2015.

51. Sachs N, de Ligt J, Kopper O, Grogola E, Bounova G, Weber F, Balgobind AV, Wind K, Gracanin A, Begthel H, et al.: A living biobank of breast cancer organoids captures disease heterogeneity. Cell 172: 373-386 e10, 2018.

52. Yan HHN, Siu HC, Law S, Ho SL, Yue SSK, Tsui WY, Chan D, Chan ASI, Ma S, Lam KOL, et al.: A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening. Cell Stem Cell 23: 882-897, e11, 2018.

53. Aggarwal V, Miranda O, Johnston PA and Sant S: Three dimensional engineered models to study hypoxia biology in breast cancer. Cancer Lett 490: 124-142, 2020.

54. Qiu GZ, Jin MZ, Dai JX, Sun W, Feng JH and Jin WL: Regulation of cell adhesion. Oncotarget 6: 7136-7150, 2015.

55. Morita M, Gravel SP, Hulea L, Larsson O, Pollak M, St-Pierre J: mTORC1 signaling controls the regulation of cell adhesion. Oncotarget 6: 7136-7150, 2015.

56. Chen L, Xu B, Liu L, Liu C, Luo Y, Chen X, Barzegar M, Chung J and Huang S: Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion. Oncotarget 6: 7136-7150, 2015.

57. Rad E, Murray JT and Tee AR: Oncogenic signalling through mechanistic target of rapamycin (mTOR): A driver of metabolic transformation and cancer progression. Cancers (Basel) 10: 5-18, 2018.